Processa Pharmaceuticals, Inc.
PCSA
$0.26
-$0.01-2.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.93M | -12.88M | -11.96M | -11.85M | -11.53M |
| Total Depreciation and Amortization | 1.20K | 1.10K | 900.00 | 700.00 | 500.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 982.30K | 831.10K | 778.30K | 716.60K | 816.90K |
| Change in Net Operating Assets | 1.22M | 1.20M | -747.10K | -112.40K | -412.50K |
| Cash from Operations | -10.73M | -10.85M | -11.93M | -11.25M | -11.12M |
| Capital Expenditure | 0.00 | -3.20K | -3.20K | -3.20K | -3.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00 | -3.20K | -3.20K | -3.20K | -3.20K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.10K | -5.70K | -5.80K | -5.20K | -3.70K |
| Issuance of Common Stock | 14.17M | 12.24M | 5.92M | 7.76M | 7.21M |
| Repurchase of Common Stock | -10.70K | -14.40K | -7.40K | -24.50K | -54.80K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 14.15M | 12.22M | 5.91M | 7.73M | 7.16M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.42M | 1.37M | -6.02M | -3.51M | -3.97M |